PE20170911A1 - Capsulas blandas de calcifediol - Google Patents
Capsulas blandas de calcifediolInfo
- Publication number
- PE20170911A1 PE20170911A1 PE2017000841A PE2017000841A PE20170911A1 PE 20170911 A1 PE20170911 A1 PE 20170911A1 PE 2017000841 A PE2017000841 A PE 2017000841A PE 2017000841 A PE2017000841 A PE 2017000841A PE 20170911 A1 PE20170911 A1 PE 20170911A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- calcifediol
- soft capsule
- soft
- capsules
- Prior art date
Links
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 title abstract 2
- 235000021318 Calcifediol Nutrition 0.000 title abstract 2
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 title abstract 2
- 229960004361 calcifediol Drugs 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000007901 soft capsule Substances 0.000 abstract 3
- KFZMGEQAYNKOFK-YZRHJBSPSA-N (214C)propan-2-ol Chemical compound [14CH](C)(C)O KFZMGEQAYNKOFK-YZRHJBSPSA-N 0.000 abstract 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 208000013038 Hypocalcemia Diseases 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 abstract 1
- 238000005115 demineralization Methods 0.000 abstract 1
- 230000002328 demineralizing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000000705 hypocalcaemia Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Paints Or Removers (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Lubricants (AREA)
- Carbon And Carbon Compounds (AREA)
Abstract
SE REFIERE A UNA CAPSULA BLANDA QUE COMPRENDE: A) UNA CUBIERTA DE CAPSULA BLANDA QUE COMPRENDE DE 40 A 80% EN PESO DE GELATINA Y DE 10 A 50% EN PESO DE UN PLASTIFICANTE TAL COMO GLICEROL, SORBITOL, PROPILENGLICOL, ENTRE OTROS; Y B) UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: i) DE 0,001 A 0,2% EN PESO DE CALCIFEDIOL, ii) DE 80 A 99,9% EN PESO DE UN COMPONENTE OLEOSO TAL COMO UN TRIGLICERIDO DE CADENA MEDIA, MIRISTATO DE ISOPROPILO, ALCOHOL DE LANOLINA, ENTRE OTROS, Y iii) DE 0,3 A 6% EN PESO DE UN DISOLVENTE ORGANICO TAL COMO ETANOL, ISOPROPANOL, ALCOHOL BENCILICO, ENTRE OTROS. DICHA CAPSULA BLANDA ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA DEFICIENCIA DE VITAMINA D, DESMINERALIZACION TAL COMO HIPOCALCEMIA E HIPOFOSFATEMIA, OSTEOPOROSIS, OSTEOPENIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170911A1 true PE20170911A1 (es) | 2017-07-12 |
Family
ID=52462260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000841A PE20170911A1 (es) | 2015-02-06 | 2016-02-05 | Capsulas blandas de calcifediol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10525018B2 (es) |
| EP (3) | EP3053598A1 (es) |
| JP (2) | JP6427270B2 (es) |
| KR (1) | KR101971384B1 (es) |
| CN (2) | CN112843014A (es) |
| AU (1) | AU2016214336B2 (es) |
| BR (1) | BR112017010657B1 (es) |
| CA (1) | CA2967170C (es) |
| CL (1) | CL2017001335A1 (es) |
| CO (1) | CO2017004545A2 (es) |
| CY (1) | CY1122976T1 (es) |
| DK (2) | DK3689380T3 (es) |
| EA (1) | EA034821B1 (es) |
| ES (2) | ES2941385T3 (es) |
| HR (1) | HRP20200859T1 (es) |
| HU (1) | HUE050133T2 (es) |
| LT (1) | LT3204047T (es) |
| MA (2) | MA41058B1 (es) |
| MD (1) | MD3204047T2 (es) |
| ME (1) | ME03739B (es) |
| MX (1) | MX367999B (es) |
| MY (2) | MY199862A (es) |
| PE (1) | PE20170911A1 (es) |
| PH (1) | PH12017501350A1 (es) |
| PL (1) | PL3204047T3 (es) |
| PT (1) | PT3204047T (es) |
| RS (2) | RS60467B1 (es) |
| SI (1) | SI3204047T1 (es) |
| SM (1) | SMT202000278T1 (es) |
| WO (1) | WO2016124724A1 (es) |
| ZA (1) | ZA201703444B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
| PE20211489A1 (es) | 2018-08-31 | 2021-08-11 | Opko Ireland Global Holdings Ltd | Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso |
| CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| CN114269348A (zh) * | 2019-08-22 | 2022-04-01 | 工业技术和生物技术公司 | 用于治疗和预防癌症的激素d(维生素d)及其衍生物 |
| CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
| CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
| CN116350598A (zh) * | 2021-12-28 | 2023-06-30 | 人福普克药业（武汉）有限公司 | 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法 |
| CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
| US12409143B2 (en) | 2022-12-14 | 2025-09-09 | R.P. Scherer Technologies, Llc | Softgel capsules and a method for preparing the softgel capsules |
| CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药（青岛）有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532126A (en) | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| DE60045101D1 (de) * | 1999-08-31 | 2010-11-25 | Chugai Pharmaceutical Co Ltd | Weichkapseln |
| US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| US20030191093A1 (en) | 2001-12-03 | 2003-10-09 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| AU2003230191A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| WO2003086415A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| PT103177A (pt) | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
| US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
| US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| CA2570649A1 (en) | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| BRPI0616330A2 (pt) | 2005-09-26 | 2011-06-14 | Novacea Inc | prevenÇço e tratamento de distérbios gastrintestinais e da bexiga associados com quimioterapia ou radioterapia usando compostos ativos com vitamina d |
| US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| SI1993559T1 (sl) * | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| US8501717B2 (en) * | 2007-02-09 | 2013-08-06 | Merck, Sharp & Dohme Corp. | Methods to treat and/or prevent mucositis |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| PT2148661E (pt) * | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| PL2321273T3 (pl) * | 2008-07-24 | 2015-05-29 | Wisconsin Alumni Res Found | Podawanie 25-hydroksy-witaminy D3 raz w tygodniu w celu utrzymania podwyższonego stężenia we krwi w stanie równowagi farmakokinetycznej |
| US8524280B2 (en) | 2008-12-15 | 2013-09-03 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en not_active Ceased
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 MY MYPI2021001039A patent/MY199862A/en unknown
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko not_active Ceased
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 HR HRP20200859TT patent/HRP20200859T1/hr unknown
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 SM SM20200278T patent/SMT202000278T1/it unknown
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170911A1 (es) | Capsulas blandas de calcifediol | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| CO2019010505A2 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR102372A1 (es) | Composición que comprende una mezcla de extractos vegetales o una mezcla de moléculas contenidas en dichos vegetales, y su utilización para actuar sobre el metabolismo glucídico y/o lipídico | |
| PE20170188A1 (es) | Formulaciones y metodos de tratamiento con queratina | |
| SV2010003777A (es) | Compuestos organicos | |
| MX2016006896A (es) | Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica. | |
| AR100306A1 (es) | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| MX2015009195A (es) | Particulas secadas por rociado estables en almacenamiento. | |
| MX2024010721A (es) | Formulaciones topicas que contienen ciclosporina y usos de las mismas. | |
| MX2019013718A (es) | Derivados de pirimidina como moduladores del receptor de pge2. | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| PE20141011A1 (es) | Formulacion farmaceutica que comprende inositol | |
| CL2018001742A1 (es) | Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas. | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| CL2016002363A1 (es) | Feromona tranquilizadora para gatos. | |
| PE20241347A1 (es) | MODULAR LA EXPRESION DE APOLIPOPROTEINA (a) | |
| MX2017014092A (es) | Metodo para obtener una biomasa de una microalga de la especie tetraselmis chuii enriquecida en superoxido dismutasa (sod). | |
| CR20120134A (es) | Derivados de pirazol que modulan la estearoil-coa-desaturasa | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CL2016001965A1 (es) | Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer |